Following an FDA advisory committee vote to restart clinical development of nerve growth factor antagonists, could this novel class of analgesics still fulfil its once-anticipated potential?
This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Holmes, D. Anti-NGF painkillers back on track?. Nat Rev Drug Discov 11, 337–338 (2012). https://doi.org/10.1038/nrd3732
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3732
- Springer Nature Limited
This article is cited by
-
Drug developers reboot anti-NGF pain programmes
Nature Reviews Drug Discovery (2015)
-
Transcriptional regulator PRDM12 is essential for human pain perception
Nature Genetics (2015)
-
Targeting Nerve Growth Factor (NGF) for Pain Management: What Does the Future Hold for NGF Antagonists?
Drugs (2014)
-
Clinical targeting of the TNF and TNFR superfamilies
Nature Reviews Drug Discovery (2013)
-
The Future of Osteoarthritis Therapeutics: Emerging Biological Therapy
Current Rheumatology Reports (2013)